Home›Trial›NCT06270719
NCT06270719Enrolling by invitation

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

Study Summary

This is a multicenter, prospective, observational Phase 4 study including a post marketing safety requirement, designed to collect both medical history data and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxeparvovec (ELEVIDYS) as part of clinical care, compared to participants with DMD receiving or prescribed to start chronic glucocorticoid treatment at the time of study enrollment in routine clinical practice.

Conditions
Duchenne Muscular Dystrophy
Interventions / Drugs
Delandistrogene MoxeparvovecStandard of Care
View on ClinicalTrials.gov ↗
Sponsor
SRPT
Sarepta Therapeutics
Gene Therapy
C61/100
Study Details
Enrollment500 participants
Primary Completion2029-12-31
Lead SponsorSarepta Therapeutics, Inc.
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: Enrolling by invitation.

Primary completion: 2029-12-31
Enrolled: 500 participants
Sponsor Catalyst Profile

Sarepta Therapeutics (SRPT) is the sponsoring company for this trial. BiotechSign currently grades this company C (61/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

SRPT Full Pipeline →All Companies →
Other Trials from Sarepta Therapeutics
NCT03992430A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participan…(PHASE3)NCT04475926A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C…NCT05967351A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxepar…(PHASE3)NCT06606340A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen…NCT05876780A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Effic…(PHASE1)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence